Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. News
Axsome Therapeutics, Inc. Quantitative Score
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Axsome Therapeutics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Axsome Therapeutics, Inc. Financials
Table Compare
Compare AXSM metrics with: | |||
|---|---|---|---|
Earnings & Growth | AXSM | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | AXSM | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | AXSM | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | AXSM | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Axsome Therapeutics, Inc. Income
Axsome Therapeutics, Inc. Balance Sheet
Axsome Therapeutics, Inc. Cash Flow
Axsome Therapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Axsome Therapeutics, Inc. Executives
| Name | Role |
|---|---|
| Dr. Herriot Tabuteau M.D. | Founder, Chairman, Chief Executive Officer & President |
| Mr. Mark L. Jacobson M.A. | Chief Operating Officer |
| Mr. Hunter Murdock Esq. | General Counsel & Secretary |
| Mr. Ari Maizel | Chief Commercial Officer |
| Darren Opland | Director of Corporate Communications |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Herriot Tabuteau M.D. | Founder, Chairman, Chief Executive Officer & President | 1968 | 1.86M | |
| Mr. Mark L. Jacobson M.A. | Chief Operating Officer | Male | 1983 | 1.05M |
| Mr. Hunter Murdock Esq. | General Counsel & Secretary | Male | 1980 | 945.7K |
| Mr. Ari Maizel | Chief Commercial Officer | Male | 1979 | 898.66K |
| Darren Opland | Director of Corporate Communications | -- |
Axsome Therapeutics, Inc. Insider Trades
| Date | 27 May |
| Name | Coleman Mark |
| Role | Director |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 3750 |
| Date | 28 May |
| Name | Coleman Mark |
| Role | Director |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 3750 |
| Date | 27 May |
| Name | Jacobson Mark L. |
| Role | Chief Operating Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 20673 |
| Date | 27 May |
| Name | Jacobson Mark L. |
| Role | Chief Operating Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 20673 |
| Date | 28 May |
| Name | Jacobson Mark L. |
| Role | Chief Operating Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 20000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 27 May | Coleman Mark | Director | Disposed | S-Sale | 3750 |
| 28 May | Coleman Mark | Director | Disposed | S-Sale | 3750 |
| 27 May | Jacobson Mark L. | Chief Operating Officer | Acquired | M-Exempt | 20673 |
| 27 May | Jacobson Mark L. | Chief Operating Officer | Disposed | S-Sale | 20673 |
| 28 May | Jacobson Mark L. | Chief Operating Officer | Acquired | M-Exempt | 20000 |